MEDLEY (FRA:3YV) YoY EBITDA Growth: 31.18% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3YV MEDLEY Inc FRA:3YV
81 GF Score
Price €13.00
GF Value €30.62
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is MEDLEY YoY EBITDA Growth?

MEDLEY FRA:3YV -4.41% 81 YoY EBITDA Growth is 31.18% as of Jun. 2026. GuruFocus rates FRA:3YV with a GF Score™ of 81/100 and a GF Value™ of €30.62 (Significantly Undervalued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MEDLEY's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 31.18%.

MEDLEY's EBITDA per Share for the six months ended in Jun. 2026 was €0.73.

MEDLEY YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for MEDLEY's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MEDLEY YoY EBITDA Growth Chart

MEDLEY Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 97.26 56.25 93.78 26.61 -22.28

MEDLEY Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.42 46.36 -18.54 -9.42 31.18
FRA:3YV
81GF Score
MEDLEY Inc FRA:3YV
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MEDLEY YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MEDLEY's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.858-1.104)/ | 1.104 |
=-22.28 %

MEDLEY's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.732-0.558)/ | 0.558 |
=31.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 31.18% mean?
MEDLEY (FRA:3YV) has a YoY EBITDA Growth of 31.18% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MEDLEY and its competitors.
Is MEDLEY's YoY EBITDA Growth too high?
MEDLEY's current YoY EBITDA Growth is 31.18%. Overall, MEDLEY has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDLEY's YoY EBITDA Growth compare to VEEV and BTSG?
MEDLEY's YoY EBITDA Growth of 31.18% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MEDLEY and its competitors. MEDLEY's current YoY EBITDA Growth is 31.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDLEY stock overvalued right now?
Based on GuruFocus' analysis, MEDLEY (FRA:3YV) is currently considered Significantly Undervalued. The stock's GF Value™ is €30.62, compared to a current price of €13.00 — trading 57.5% below its estimated fair value. The current YoY EBITDA Growth is 31.18%. MEDLEY's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For MEDLEY (FRA:3YV), the current YoY EBITDA Growth is 31.18% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MEDLEY (FRA:3YV) Overvalued in 2026?

Based on GuruFocus' analysis, MEDLEY stock appears to be undervalued. The current stock price of €13.00 is trading 57.5% below its estimated GF Value™ of €30.62. GuruFocus considers MEDLEY to be Significantly Undervalued.

Key valuation signals for FRA:3YV:

  • YoY EBITDA Growth: 31.18%
  • GF Value™: €30.62 vs. price of €13.00 (57.5% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the FRA:3YV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MEDLEY Business Description

Other Exchanges MDLYF:USA4480:Japan
Address 3-2-1 Roppongi, Minato-ku, 22nd Floor Sumitomo Fudosan Roppongi Grand Tower, Tokyo, JPN, 106-6222
MEDLEY Inc is engaged in providing medical information service for patients, and nursing care, a nursing care information service for citizens resolving issues in the field of medical healthcare. It provides its services through two platforms, Recruitment Platform Business which provides human resource recruitment systems in the medical and healthcare field and related businesses; and Medical Platform Business that is a telemedicine system for both patients and medical institutions.
81GF Score

Get the complete analysis for FRA:3YV

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00
Price
€30.62
GF Value